CC Chemokine Receptors in Lung Adenocarcinoma: The Inflammation-Related Prognostic Biomarkers and Immunotherapeutic Targets

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int j Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.31937
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Shi J, Hua X, Zhu B, et al. Somatic genomics and clinical features of lung adenocarcinoma: a retrospective study. PLoS Med. 2016;13(12):e1002162. doi:10.1371/journal.pmed.1002162
   PubMed Web of Science ®Google Scholar
• Liang Y, Wakelee HA. Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2013;2(5):403–410. doi:10.3978/j.issn.2218-6751.2013.07.01
   PubMedGoogle Scholar
• Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9). doi:10.1098/rsob.170070
   PubMed Web of Science ®Google Scholar
• Heigener DF, Reck M, Gatzemeier U. [Non-small cell lung cancer - diagnostics and stage-adapted therapy]. Medizinische Klinik (Munich, Germany: 1983). 2007;102(12):981–8;quiz 989–90. German. doi:10.1007/s00063-007-1122-4
   Google Scholar
• Carter BW, Godoy MC, Wu CC, Erasmus JJ, Truong MT. Current controversies in lung cancer staging. J Thorac Imaging. 2016;31(4):201–214. doi:10.1097/rti.0000000000000213
   PubMed Web of Science ®Google Scholar
• Carter BW, Lichtenberger JP 3rd, Benveniste MK, et al. Revisions to the TNM Staging of lung cancer: rationale, significance, and clinical application. Radiographics. 2018;38(2):374–391. doi:10.1148/rg.2018170081
   PubMed Web of Science ®Google Scholar
• Trzaskowski B, Latek D, Yuan S, Ghoshdastider U, Debinski A, Filipek S. Action of molecular switches in GPCRs–theoretical and experimental studies. Curr Med Chem. 2012;19(8):1090–1109. doi:10.2174/092986712799320556
   PubMed Web of Science ®Google Scholar
• Chemokine/chemokine receptor nomenclature. Cytokine. 2003;21(1):48–49. doi:10.1016/s1043-4666(02)00493-3
   PubMed Web of Science ®Google Scholar
• Chemokine/chemokine receptor nomenclature. J Leukoc Biol. 2001;70(3):465–466.
   PubMedGoogle Scholar
• Rodríguez-Fernández JL, Criado-García O. The Chemokine Receptor CCR7 uses distinct signaling modules with biased functionality to regulate dendritic cells. Front Immunol. 2020;11:528. doi:10.3389/fimmu.2020.00528
   PubMed Web of Science ®Google Scholar
• Roubeix C, Dominguez E, Raoul W, et al. Mo-derived perivascular macrophage recruitment protects against endothelial cell death in retinal vein occlusion. J Neuroinflammation. 2019;16(1):157. doi:10.1186/s12974-019-1547-8
   PubMedGoogle Scholar
• Wang T, Zhou Q, Zeng H, et al. CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer. Cancer Immunol Immunother. 2020;69(9):1855–1867. doi:10.1007/s00262-020-02583-y
   PubMed Web of Science ®Google Scholar
• Kadomoto S, Izumi K, Mizokami A. The CCL20-CCR6 axis in cancer progression. Int J Mol Sci. 2020;21. doi:10.3390/ijms21155186.
   PubMedGoogle Scholar
• Lokeshwar BL, Kallifatidis G, Hoy JJ. Atypical chemokine receptors in tumor cell growth and metastasis. Adv Cancer Res. 2020;145:1–27. doi:10.1016/bs.acr.2019.12.002
   PubMed Web of Science ®Google Scholar
• Groblewska M, Litman-Zawadzka A, Mroczko B. The role of selected chemokines and their receptors in the development of gliomas. Int J Mol Sci. 2020;21(10):3704. doi:10.3390/ijms21103704
   PubMed Web of Science ®Google Scholar
• White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation–therapeutic opportunities and pharmacological challenges. Pharmacol Rev. 2013;65(1):47–89. doi:10.1124/pr.111.005074
   PubMed Web of Science ®Google Scholar
• Nishimura M, Kuboi Y, Muramoto K, Kawano T, Imai T. Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann N Y Acad Sci. 2009;1173(1):350–356. doi:10.1111/j.1749-6632.2009.04738.x
   PubMedGoogle Scholar
• Trivedi PJ, Adams DH. Chemokines and chemokine receptors as therapeutic targets in inflammatory bowel disease; pitfalls and promise. J Crohn’s & Colitis. 2018;12(suppl_2):S641–s652. doi:10.1093/ecco-jcc/jjx145
   PubMedGoogle Scholar
• White G, Iqbal A, Greaves DJPR. CC chemokine receptors and chronic inflammation therapeutic opportunities and pharmacological challenges. 2013;65:47–89.
   Google Scholar
• Okayama H, Kohno T, Ishii Y, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res. 2012;72(1):100–111. doi:10.1158/0008-5472.Can-11-1403
   PubMed Web of Science ®Google Scholar
• Chanrion M, Negre V, Fontaine H, et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res. 2008;14(6):1744–1752. doi:10.1158/1078-0432.Ccr-07-1833
   PubMed Web of Science ®Google Scholar
• Laurent C, Valet F, Planque N, et al. High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res. 2011;71(3):666–674. doi:10.1158/0008-5472.Can-10-0605
   PubMed Web of Science ®Google Scholar
• Smith JJ, Deane NG, Wu F, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010;138(3):958–968. doi:10.1053/j.gastro.2009.11.005
   PubMed Web of Science ®Google Scholar
• Tomida S, Takeuchi T, Shimada Y, et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol. 2009;27(17):2793–2799. doi:10.1200/jco.2008.19.7053
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY). 2004;6(1):1–6. doi:10.1016/s1476-5586(04)80047-2
   PubMed Web of Science ®Google Scholar
• Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia (New York, NY). 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–w102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227. doi:10.1038/s41598-018-27521-y
   PubMed Web of Science ®Google Scholar
• Aguirre-Gamboa R, Gomez-Rueda H, Martínez-Ledesma E, et al. SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One. 2013;8(9):e74250. doi:10.1371/journal.pone.0074250
   PubMed Web of Science ®Google Scholar
• Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2018;10(3):277–288. doi:10.2217/epi-2017-0118
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhao N, Zhang X, et al. SurvivalMeth: a web server to investigate the effect of DNA methylation-related functional elements on prognosis. Brief Bioinform. 2020. doi:10.1093/bib/bbaa162
   Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.Cd-12-0095
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–d613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–d368. doi:10.1093/nar/gkw937
   PubMed Web of Science ®Google Scholar
• Warde-Farley D, Donaldson SL, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(suppl_2):W214–W220. doi:10.1093/nar/gkq537
   PubMed Web of Science ®Google Scholar
• da Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13. doi:10.1093/nar/gkn923
   PubMed Web of Science ®Google Scholar
• da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/nprot.2008.211
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. doi:10.1038/s41467-019-09234-6
   PubMed Web of Science ®Google Scholar
• Han H, Cho JW, Lee S, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res. 2018;46(D1):D380–d386. doi:10.1093/nar/gkx1013
   PubMed Web of Science ®Google Scholar
• Han H, Shim H, Shin D, et al. TRRUST: a reference database of human transcriptional regulatory interactions. Sci Rep. 2015;5:11432. doi:10.1038/srep11432
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–d963. doi:10.1093/nar/gkx1090
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174. doi:10.1186/s13059-016-1028-7
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.Can-17-0307
   PubMed Web of Science ®Google Scholar
• Murphy PM. CC Chemokine Receptors. In: Enna SJ, Bylund DB, editors. xPharm: The Comprehensive Pharmacology Reference. Elsevier; 2007:1–2.
   Google Scholar
• Fantuzzi L, Tagliamonte M, Gauzzi MC, Lopalco L. Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cell Mol Life Sci. 2019;76(24):4869–4886. doi:10.1007/s00018-019-03255-6
   PubMed Web of Science ®Google Scholar
• Raghu H, Lepus CM, Wang Q, et al. CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis. Ann Rheum Dis. 2017;76(5):914–922. doi:10.1136/annrheumdis-2016-210426
   PubMed Web of Science ®Google Scholar
• Scheu S, Ali S, Ruland C, Arolt V, Alferink J. The C-C Chemokines CCL17 and CCL22 and their receptor CCR4 in CNS autoimmunity. Int J Mol Sci. 2017;18(11). doi:10.3390/ijms18112306
   PubMed Web of Science ®Google Scholar
• Mollica Poeta V, Massara M, Capucetti A, Bonecchi R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Mini Rev. 2019;10(379). doi:10.3389/fimmu.2019.00379
   Google Scholar
• Rizeq B, Malki MI. The role of CCL21/CCR7 chemokine axis in breast cancer progression. Cancers. 2020;12(4):1036. doi:10.3390/cancers12041036
   PubMed Web of Science ®Google Scholar
• Mollica Poeta V, Massara M, Capucetti A, Bonecchi R. Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol. 2019;10:379. doi:10.3389/fimmu.2019.00379
   PubMed Web of Science ®Google Scholar
• Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008;267(2):226–244. doi:10.1016/j.canlet.2008.04.050
   PubMed Web of Science ®Google Scholar
• Kitamura T, Fujishita T, Loetscher P, et al. Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci U S A. 2010;107(29):13063–13068. doi:10.1073/pnas.1002372107
   PubMed Web of Science ®Google Scholar
• Moore DC, Elmes JB, Shibu PA, Larck C, Park SI. Mogamulizumab: an Anti-CC chemokine receptor 4 antibody for T-Cell lymphomas. Ann Pharmacother. 2020;54(4):371–379. doi:10.1177/1060028019884863
   PubMed Web of Science ®Google Scholar
• Makita S, Tobinai K. Mogamulizumab for the treatment of T-cell lymphoma. Expert Opin Biol Ther. 2017;17(9):1145–1153. doi:10.1080/14712598.2017.1347634
   PubMed Web of Science ®Google Scholar
• Bikfalvi A, Billottet C. The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment. Am J Physiol Cell Physiol. 2020;318(3):C542–c554. doi:10.1152/ajpcell.00378.2019
   PubMed Web of Science ®Google Scholar
• Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008;8(5):362–371. doi:10.1038/nri2297
   PubMed Web of Science ®Google Scholar
• Kim J, Yang YL, Jang YS. Human β-defensin 2 is involved in CCR2-mediated Nod2 signal transduction, leading to activation of the innate immune response in macrophages. Immunobiology. 2019;224(4):502–510. doi:10.1016/j.imbio.2019.05.004
   PubMed Web of Science ®Google Scholar
• Lee AYS, The KH. CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology. Immunobiology. 2019;224(3):449–454. doi:10.1016/j.imbio.2019.01.005
   PubMed Web of Science ®Google Scholar
• Lee JH, Cho YS, Lee JY, et al. The chemokine receptor CCR4 is expressed and associated with a poor prognosis in patients with gastric cancer. Ann Surg. 2009;249(6):933–941. doi:10.1097/SLA.0b013e3181a77ccc
   PubMed Web of Science ®Google Scholar
• Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9(10 Pt 1):3625–3634.
   PubMed Web of Science ®Google Scholar
• Li YL, Shi ZH, Wang X, Gu KS, Zhai ZM. Prognostic significance of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in diffuse large B cell lymphoma. Ann Hematol. 2019;98(2):413–422. doi:10.1007/s00277-018-3522-3
   PubMed Web of Science ®Google Scholar
• Labovsky V, Martinez LM, Davies KM, et al. Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer. BMC Cancer. 2017;17(1):280. doi:10.1186/s12885-017-3259-8
   PubMedGoogle Scholar
• Itakura M, Terashima Y, Shingyoji M, et al. High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients. Br J Cancer. 2013;109(5):1100–1108. doi:10.1038/bjc.2013.440
   PubMed Web of Science ®Google Scholar
• González-Arriagada WA, Lozano-Burgos C, Zúñiga-Moreta R, González-Díaz P, Coletta RD. Clinicopathological significance of chemokine receptor (CCR1, CCR3, CCR4, CCR5, CCR7 and CXCR4) expression in head and neck squamous cell carcinomas. J Oral Pathol Med. 2018;47(8):755–763. doi:10.1111/jop.12736
   PubMed Web of Science ®Google Scholar
• Zhong Y, Jiang L, Lin H, et al. Expression of CC chemokine receptor 9 predicts poor prognosis in patients with lung adenocarcinoma. Diagn Pathol. 2015;10:101. doi:10.1186/s13000-015-0341-x
   PubMed Web of Science ®Google Scholar
• Yu J, Tao S, Hu P, et al. CCR7 promote lymph node metastasis via regulating VEGF-C/D-R3 pathway in lung adenocarcinoma. J Cancer. 2017;8(11):2060–2068. doi:10.7150/jca.19069
   PubMed Web of Science ®Google Scholar
• Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int j Cancer. 2003;105(2):186–189. doi:10.1002/ijc.11063
   PubMed Web of Science ®Google Scholar
• Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659–702. doi:10.1146/annurev-immunol-032713-120145
   PubMed Web of Science ®Google Scholar
• Korbecki J, Grochans S, Gutowska I, Barczak K, Baranowska-Bosiacka I. CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands. Int J Mol Sci. 2020;21. doi:10.3390/ijms21207619.
   Web of Science ®Google Scholar
• Chen KJ, Lin SZ, Zhou L, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One. 2011;6(9):e24671. doi:10.1371/journal.pone.0024671
   PubMed Web of Science ®Google Scholar
• Yu Q, Lou XM, He Y. Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathway. PLoS One. 2015;10(3):e0120855. doi:10.1371/journal.pone.0120855
   PubMed Web of Science ®Google Scholar
• Zhang CY, Qi Y, Li XN, et al. The role of CCL20/CCR6 axis in recruiting Treg cells to tumor sites of NSCLC patients. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2015;69:242–248. doi:10.1016/j.biopha.2014.12.008
   PubMed Web of Science ®Google Scholar
• Nandi B, Shapiro M, Samur MK, et al. Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages. Oncoimmunology. 2016;5(8):e1189052. doi:10.1080/2162402x.2016.1189052
   PubMed Web of Science ®Google Scholar